Clinical studies thus far include targeting molecules that fall directly within the canonical MAPK pathway, such as MEK in melanoma [35, 36] and molecules that are membrane receptors activated due to feedback mechanisms, such as EGFR in colorectal cancer [37]. Here, EGFR is linked to colorectal cancer.